Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 6
1964 10
1965 2
1966 7
1967 9
1968 20
1969 20
1970 20
1971 26
1972 14
1973 22
1974 32
1975 29
1976 20
1977 15
1978 23
1979 14
1980 30
1981 26
1982 30
1983 28
1984 29
1985 34
1986 34
1987 43
1988 52
1989 83
1990 77
1991 73
1992 74
1993 83
1994 77
1995 96
1996 102
1997 101
1998 67
1999 84
2000 99
2001 98
2002 96
2003 116
2004 109
2005 121
2006 117
2007 99
2008 86
2009 101
2010 105
2011 96
2012 97
2013 101
2014 104
2015 85
2016 88
2017 110
2018 105
2019 81
2020 62
2021 94
2022 81
2023 63
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

3,661 results

Results by year

Filters applied: . Clear all
Page 1
Cancer-related hypercalcemia and potential treatments.
Almuradova E, Cicin I. Almuradova E, et al. Front Endocrinol (Lausanne). 2023 Mar 22;14:1039490. doi: 10.3389/fendo.2023.1039490. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37033238 Free PMC article. Review.
The most common cause of hypercalcemia in hospitalized patients is hypercalcemia due to malignancy.This clinical problem is seen in patients with both solid tumors and patients with hematologic malignancies. Hypercalcemia is associated with a poor prognosis i …
The most common cause of hypercalcemia in hospitalized patients is hypercalcemia due to malignancy.This clinical problem is se …
Renal sarcoidosis.
Calatroni M, Moroni G, Reggiani F, Ponticelli C. Calatroni M, et al. J Nephrol. 2023 Jan;36(1):5-15. doi: 10.1007/s40620-022-01369-y. Epub 2022 Jun 27. J Nephrol. 2023. PMID: 35761015 Review.
The main kidney abnormalities in sarcoidosis are granulomatous interstitial nephritis (GIN) and hypercalcemia-related disorders. The clinical diagnosis is difficult. ...Early diagnosis and prompt treatment with corticosteroids can improve the prognosis. Hypercalcemia …
The main kidney abnormalities in sarcoidosis are granulomatous interstitial nephritis (GIN) and hypercalcemia-related disorders. The …
Familial hypocalciuric hypercalcemia and related disorders.
Lee JY, Shoback DM. Lee JY, et al. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):609-619. doi: 10.1016/j.beem.2018.05.004. Epub 2018 May 26. Best Pract Res Clin Endocrinol Metab. 2018. PMID: 30449544 Free PMC article. Review.
Familial hypocalciuric hypercalcemia (FHH) causes hypercalcemia by three genetic mechanisms: inactivating mutations in the calcium-sensing receptor, the G-protein subunit alpha(11), or adaptor-related protein complex 2, sigma 1 subunit. ...The calcimimetic cinacalce …
Familial hypocalciuric hypercalcemia (FHH) causes hypercalcemia by three genetic mechanisms: inactivating mutations in the cal …
Treatment of Hypercalcemia of Malignancy.
Chakhtoura M, El-Hajj Fuleihan G. Chakhtoura M, et al. Endocrinol Metab Clin North Am. 2021 Dec;50(4):781-792. doi: 10.1016/j.ecl.2021.08.002. Endocrinol Metab Clin North Am. 2021. PMID: 34774248 Review.
The treatment of hypercalcemia of malignancy (HCM) consists of enhancing renal calcium excretion, mostly through hydration with isotonic fluids and the use of antiresorptive therapies. ...Subcutaneous denosumab is used for bisphosphonate-refractory hypercalcemia and …
The treatment of hypercalcemia of malignancy (HCM) consists of enhancing renal calcium excretion, mostly through hydration with isoto …
Drug-Related Hypercalcemia.
Lecoq AL, Livrozet M, Blanchard A, Kamenický P. Lecoq AL, et al. Endocrinol Metab Clin North Am. 2021 Dec;50(4):743-752. doi: 10.1016/j.ecl.2021.08.001. Endocrinol Metab Clin North Am. 2021. PMID: 34774245 Review.
This review focuses on the commonly prescribed medicaments that can be responsible for hypercalcemia, considering the prevalence, the predominant pathophysiological mechanisms, and the optimal medical management of each drug-induced hypercalcemia. ...Lithium causes …
This review focuses on the commonly prescribed medicaments that can be responsible for hypercalcemia, considering the prevalence, the …
Primary hyperparathyroidism.
Walker MD, Silverberg SJ. Walker MD, et al. Nat Rev Endocrinol. 2018 Feb;14(2):115-125. doi: 10.1038/nrendo.2017.104. Epub 2017 Sep 8. Nat Rev Endocrinol. 2018. PMID: 28885621 Free PMC article. Review.
PHPT is a common endocrine disorder that is characterized by hypercalcaemia and elevated or inappropriately normal serum levels of parathyroid hormone. Most often, the presentation of PHPT is asymptomatic in regions of the world where serum levels of calcium are routinely …
PHPT is a common endocrine disorder that is characterized by hypercalcaemia and elevated or inappropriately normal serum levels of pa …
A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia.
Tonon CR, Silva TAAL, Pereira FWL, Queiroz DAR, Junior ELF, Martins D, Azevedo PS, Okoshi MP, Zornoff LAM, de Paiva SAR, Minicucci MF, Polegato BF. Tonon CR, et al. Med Sci Monit. 2022 Feb 26;28:e935821. doi: 10.12659/MSM.935821. Med Sci Monit. 2022. PMID: 35217631 Free PMC article. Review.
Various mechanisms are involved in the pathophysiology of hypercalcemia, such as excessive PTH production, production of parathyroid hormone-related protein (PTHrp), bone metastasis, extrarenal activation of vitamin D, and ectopic PTH secretion. ...This review aims to prov …
Various mechanisms are involved in the pathophysiology of hypercalcemia, such as excessive PTH production, production of parathyroid …
A practical approach to hypercalcemia.
Carroll MF, Schade DS. Carroll MF, et al. Am Fam Physician. 2003 May 1;67(9):1959-66. Am Fam Physician. 2003. PMID: 12751658 Free article. Review.
Hypercalcemia is a disorder commonly encountered by primary care physicians. ...Clinical manifestations affect the neuromuscular, gastrointestinal, renal, skeletal, and cardiovascular systems. The most common causes of hypercalcemia are primary hyperparathyroidism a …
Hypercalcemia is a disorder commonly encountered by primary care physicians. ...Clinical manifestations affect the neuromuscular, gas …
Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature.
Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Asonitis N, et al. Horm Metab Res. 2019 Dec;51(12):770-778. doi: 10.1055/a-1049-0647. Epub 2019 Dec 11. Horm Metab Res. 2019. PMID: 31826272 Review.
Hypercalcemia of malignancy is the most common life-threatening metabolic disorder in patients with advanced stage cancers and is a sign of poor prognosis. ...Several mechanisms have been implicated in the development of hypercalcemia of malignancy amongst them the …
Hypercalcemia of malignancy is the most common life-threatening metabolic disorder in patients with advanced stage cancers and is a s …
Lithium-associated hyperparathyroidism.
Mifsud S, Cilia K, Mifsud EL, Gruppetta M. Mifsud S, et al. Br J Hosp Med (Lond). 2020 Nov 2;81(11):1-9. doi: 10.12968/hmed.2020.0457. Epub 2020 Nov 17. Br J Hosp Med (Lond). 2020. PMID: 33263481 Review.
Treatment with lithium can give rise to various endocrine and metabolic abnormalities, including thyroid dysfunction, nephrogenic diabetes insipidus and hypercalcaemia. Lithium may induce hypercalcaemia through both acute and chronic effects. The initial acute effec …
Treatment with lithium can give rise to various endocrine and metabolic abnormalities, including thyroid dysfunction, nephrogenic diabetes i …
3,661 results